Finally, modulation of Brap may be a possible avenue to modulate Hippo pathway response under these conditions, which has relevance to human liver disease, including NASH and nonalcoholic fatty liver disease. This evidence concerns the gene BRAP and metabolic dysfunction-associated steatohepatitis.